BRD4 degradation blocks expression of MYC and multiple forms of stem cell resistance in Ph


Journal

American journal of hematology
ISSN: 1096-8652
Titre abrégé: Am J Hematol
Pays: United States
ID NLM: 7610369

Informations de publication

Date de publication:
09 2022
Historique:
revised: 23 06 2022
received: 08 03 2022
accepted: 02 07 2022
pubmed: 8 7 2022
medline: 17 8 2022
entrez: 7 7 2022
Statut: ppublish

Résumé

In most patients with chronic myeloid leukemia (CML) clonal cells can be kept under control by BCR::ABL1 tyrosine kinase inhibitors (TKI). However, overt resistance or intolerance against these TKI may occur. We identified the epigenetic reader BRD4 and its downstream-effector MYC as growth regulators and therapeutic targets in CML cells. BRD4 and MYC were found to be expressed in primary CML cells, CD34

Identifiants

pubmed: 35794848
doi: 10.1002/ajh.26650
pmc: PMC9546315
doi:

Substances chimiques

BRD4 protein, human 0
Cell Cycle Proteins 0
MYC protein, human 0
Nuclear Proteins 0
Protein Kinase Inhibitors 0
Proto-Oncogene Proteins c-myc 0
Transcription Factors 0
Fusion Proteins, bcr-abl EC 2.7.10.2

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1215-1225

Informations de copyright

© 2022 The Authors. American Journal of Hematology published by Wiley Periodicals LLC.

Références

Nature. 2015 Sep 24;525(7570):543-547
pubmed: 26367798
Haematologica. 2007 Sep;92(9):1238-41
pubmed: 17768119
Nat Chem Biol. 2012 Nov;8(11):905-912
pubmed: 23023260
PLoS One. 2009 Jul 01;4(7):e6124
pubmed: 19568437
Nature. 2010 Dec 23;468(7327):1067-73
pubmed: 20871596
Clin Pharmacol Ther. 2008 Feb;83(2):258-64
pubmed: 17568400
Nature. 2015 Sep 24;525(7570):538-42
pubmed: 26367796
Cancer Cell. 2002 Jun;1(5):479-92
pubmed: 12124177
Science. 2015 Jun 19;348(6241):1376-81
pubmed: 25999370
N Engl J Med. 2006 Jun 15;354(24):2542-51
pubmed: 16775235
Blood. 2008 Jul 1;112(1):53-5
pubmed: 18403620
Blood. 2013 Jan 17;121(3):489-98
pubmed: 23223358
Cancer Cell. 2014 Sep 8;26(3):428-442
pubmed: 25132497
Clin Cancer Res. 2008 Jul 15;14(14):4392-9
pubmed: 18628453
Science. 2001 Aug 3;293(5531):876-80
pubmed: 11423618
Leukemia. 2007 May;21(5):926-35
pubmed: 17330101
Biochem Pharmacol. 2010 Sep 1;80(5):602-12
pubmed: 20382130
N Engl J Med. 2006 Dec 7;355(23):2408-17
pubmed: 17151364
Science. 2004 Jul 16;305(5682):399-401
pubmed: 15256671
Oncotarget. 2012 Dec;3(12):1588-99
pubmed: 23249862
J Natl Compr Canc Netw. 2008 Mar;6 Suppl 2:S37-42; quiz S43-S44
pubmed: 18397680
Blood. 1995 Jul 15;86(2):726-36
pubmed: 7606002
Haematologica. 2005 Apr;90(4):534-41
pubmed: 15820950
Cancer Cell. 2005 Feb;7(2):129-41
pubmed: 15710326
J Clin Invest. 2011 Jan;121(1):396-409
pubmed: 21157039
Cancer Cell. 2009 Nov 6;16(5):401-12
pubmed: 19878872
N Engl J Med. 2002 Feb 28;346(9):645-52
pubmed: 11870241
Cancer Treat Res. 2004;119:239-70
pubmed: 15164881
Cancer Cell. 2002 Aug;2(2):117-25
pubmed: 12204532
Mol Cell. 2017 Jul 6;67(1):5-18.e19
pubmed: 28673542
Leukemia. 2018 Apr;32(4):1016-1022
pubmed: 29249817
Adv Cancer Res. 2015;127:227-52
pubmed: 26093902
Nat Rev Cancer. 2007 May;7(5):345-56
pubmed: 17457302
N Engl J Med. 2012 Aug 16;367(7):647-57
pubmed: 22894577
N Engl J Med. 2019 Dec 12;381(24):2315-2326
pubmed: 31826340
N Engl J Med. 2012 Mar 8;366(10):960-1
pubmed: 22397660
Nature. 2011 Aug 03;478(7370):524-8
pubmed: 21814200
Hematol Oncol Clin North Am. 2004 Jun;18(3):545-68, vii-viii
pubmed: 15271392
Trends Mol Med. 2007 Nov;13(11):470-81
pubmed: 17981087
Haematologica. 2018 Jan;103(1):e10-e12
pubmed: 28983061
Blood. 2000 Nov 15;96(10):3343-56
pubmed: 11071626
Cell Rep. 2017 Feb 28;18(9):2162-2174
pubmed: 28249162
Leukemia. 2015 Nov;29(11):2230-7
pubmed: 26055303
Stem Cells Transl Med. 2018 Mar;7(3):305-314
pubmed: 29418079
N Engl J Med. 2003 Mar 13;348(11):994-1004
pubmed: 12637609
Blood. 2013 Mar 7;121(10):1824-38
pubmed: 23299311
J Clin Oncol. 2008 Jun 10;26(17):2911-5
pubmed: 18539972
N Engl J Med. 2013 Nov 7;369(19):1783-96
pubmed: 24180494
J Natl Compr Canc Netw. 2008 Mar;6 Suppl 2:S11-S21
pubmed: 18397677
Cell Cycle. 2006 Dec;5(24):2862-6
pubmed: 17172863
Br J Haematol. 2008 Jul;142(3):361-78
pubmed: 18540942
Nat Rev Cancer. 2012 Nov;12(11):767-75
pubmed: 23051844
N Engl J Med. 2006 Jun 15;354(24):2531-41
pubmed: 16775234
Am J Hematol. 2022 Sep;97(9):1215-1225
pubmed: 35794848
N Engl J Med. 2001 Apr 5;344(14):1031-7
pubmed: 11287972

Auteurs

Barbara Peter (B)

Ludwig Boltzmann Institute for Hematology and Oncology, Medical University of Vienna, Vienna, Austria.
Department of Internal Medicine I, Division of Hematology & Hemostaseology, Medical University of Vienna, Vienna, Austria.

Gregor Eisenwort (G)

Ludwig Boltzmann Institute for Hematology and Oncology, Medical University of Vienna, Vienna, Austria.
Department of Internal Medicine I, Division of Hematology & Hemostaseology, Medical University of Vienna, Vienna, Austria.

Irina Sadovnik (I)

Ludwig Boltzmann Institute for Hematology and Oncology, Medical University of Vienna, Vienna, Austria.
Department of Internal Medicine I, Division of Hematology & Hemostaseology, Medical University of Vienna, Vienna, Austria.

Karin Bauer (K)

Ludwig Boltzmann Institute for Hematology and Oncology, Medical University of Vienna, Vienna, Austria.
Department of Internal Medicine I, Division of Hematology & Hemostaseology, Medical University of Vienna, Vienna, Austria.

Michael Willmann (M)

Ludwig Boltzmann Institute for Hematology and Oncology, Medical University of Vienna, Vienna, Austria.
Department for Companion Animals and Horses, University Clinic for Small Animals, Internal Medicine Small Animals, University of Veterinary Medicine Vienna, Vienna, Austria.

Thomas Rülicke (T)

Ludwig Boltzmann Institute for Hematology and Oncology, Medical University of Vienna, Vienna, Austria.
Institute of Laboratory Animal Science, University of Veterinary Medicine Vienna, Vienna, Austria.

Daniela Berger (D)

Department of Internal Medicine I, Division of Hematology & Hemostaseology, Medical University of Vienna, Vienna, Austria.

Gabriele Stefanzl (G)

Department of Internal Medicine I, Division of Hematology & Hemostaseology, Medical University of Vienna, Vienna, Austria.

Georg Greiner (G)

Ludwig Boltzmann Institute for Hematology and Oncology, Medical University of Vienna, Vienna, Austria.
Department of Laboratory Medicine, Medical University of Vienna, Vienna, Austria.

Gregor Hoermann (G)

Ludwig Boltzmann Institute for Hematology and Oncology, Medical University of Vienna, Vienna, Austria.
Department of Laboratory Medicine, Medical University of Vienna, Vienna, Austria.
MLL Munich Leukemia Laboratory, Munich, Germany.

Alexandra Keller (A)

Ludwig Boltzmann Institute for Hematology and Oncology, Medical University of Vienna, Vienna, Austria.
Department of Internal Medicine I, Division of Hematology & Hemostaseology, Medical University of Vienna, Vienna, Austria.

Dominik Wolf (D)

Department of Hematology and Oncology, Innsbruck Medical University, Innsbruck, Austria.
Department of Hematology, Oncology and Rheumatology, Center of Integrated Oncology Cologne Bonn, University Hospital of Bonn, Bonn, Germany.

Martin Čulen (M)

Department of Internal Medicine, Hematology and Oncology, Faculty of Medicine, Masaryk University, Brno, Czech Republic.
Department of Internal Medicine, Hematology and Oncology, University Hospital Brno, Brno, Czech Republic.

Georg E Winter (GE)

CeMM-Research Center for Molecular Medicine of the Austrian Academy of Sciences, Vienna, Austria.

Thomas Hoffmann (T)

Research Institute of Molecular Pathology (IMP), Vienna BioCenter (VBC), Vienna, Austria.

Ana-Iris Schiefer (AI)

Department of Pathology, Medical University of Vienna, Vienna, Austria.

Wolfgang R Sperr (WR)

Ludwig Boltzmann Institute for Hematology and Oncology, Medical University of Vienna, Vienna, Austria.
Department of Internal Medicine I, Division of Hematology & Hemostaseology, Medical University of Vienna, Vienna, Austria.

Johannes Zuber (J)

Research Institute of Molecular Pathology (IMP), Vienna BioCenter (VBC), Vienna, Austria.
Medical University of Vienna, Vienna BioCenter (VBC), Vienna, Austria.

Jiří Mayer (J)

Department of Internal Medicine, Hematology and Oncology, Faculty of Medicine, Masaryk University, Brno, Czech Republic.
Department of Internal Medicine, Hematology and Oncology, University Hospital Brno, Brno, Czech Republic.

Peter Valent (P)

Ludwig Boltzmann Institute for Hematology and Oncology, Medical University of Vienna, Vienna, Austria.
Department of Internal Medicine I, Division of Hematology & Hemostaseology, Medical University of Vienna, Vienna, Austria.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH